Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 15 | 2023 | 706 | 2.770 |
Why?
|
| Anemia, Sickle Cell | 5 | 2023 | 183 | 1.840 |
Why?
|
| Sickle Cell Trait | 2 | 2022 | 17 | 1.630 |
Why?
|
| HIV Infections | 8 | 2023 | 2303 | 0.940 |
Why?
|
| Virus Replication | 7 | 2021 | 278 | 0.900 |
Why?
|
| Protein Phosphatase 1 | 7 | 2022 | 62 | 0.760 |
Why?
|
| Cyclin-Dependent Kinase 9 | 5 | 2021 | 37 | 0.710 |
Why?
|
| Gene Expression Regulation, Viral | 6 | 2021 | 110 | 0.710 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2018 | 31 | 0.670 |
Why?
|
| Anti-HIV Agents | 3 | 2017 | 420 | 0.590 |
Why?
|
| Curcumin | 2 | 2017 | 74 | 0.530 |
Why?
|
| Iron Chelating Agents | 2 | 2017 | 21 | 0.530 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 57 | 0.520 |
Why?
|
| Transcription, Genetic | 7 | 2022 | 578 | 0.510 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2021 | 53 | 0.480 |
Why?
|
| Antiviral Agents | 4 | 2022 | 157 | 0.480 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 44 | 0.470 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 357 | 0.430 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 169 | 0.310 |
Why?
|
| Macrophages | 3 | 2020 | 439 | 0.280 |
Why?
|
| Ebolavirus | 2 | 2018 | 42 | 0.270 |
Why?
|
| Hemolysis | 2 | 2023 | 40 | 0.260 |
Why?
|
| Humans | 21 | 2024 | 37093 | 0.260 |
Why?
|
| Heme Oxygenase-1 | 2 | 2015 | 51 | 0.240 |
Why?
|
| Iron | 2 | 2023 | 225 | 0.230 |
Why?
|
| Mucins | 1 | 2023 | 35 | 0.230 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 234 | 0.230 |
Why?
|
| Phosphorylation | 7 | 2022 | 928 | 0.220 |
Why?
|
| Host-Pathogen Interactions | 3 | 2020 | 186 | 0.220 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 431 | 0.220 |
Why?
|
| Cyclin T | 3 | 2021 | 16 | 0.220 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 160 | 0.210 |
Why?
|
| RNA, Viral | 4 | 2021 | 301 | 0.210 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2021 | 20 | 0.200 |
Why?
|
| Viruses | 1 | 2020 | 36 | 0.180 |
Why?
|
| Serine | 2 | 2018 | 75 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 64 | 0.180 |
Why?
|
| Mice | 7 | 2023 | 5913 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1518 | 0.180 |
Why?
|
| Kidney | 2 | 2020 | 337 | 0.170 |
Why?
|
| Drug Stability | 2 | 2018 | 116 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2018 | 15 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 26 | 0.160 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 15 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.150 |
Why?
|
| Animals | 10 | 2023 | 15081 | 0.150 |
Why?
|
| Viral Proteins | 2 | 2018 | 174 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 643 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 237 | 0.140 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2015 | 33 | 0.130 |
Why?
|
| Enzyme Induction | 1 | 2015 | 53 | 0.130 |
Why?
|
| Half-Life | 1 | 2015 | 54 | 0.130 |
Why?
|
| Proviruses | 1 | 2015 | 29 | 0.130 |
Why?
|
| Virus Activation | 1 | 2015 | 35 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2023 | 308 | 0.130 |
Why?
|
| Isoquinolines | 1 | 2015 | 45 | 0.130 |
Why?
|
| Cyclin A | 1 | 2014 | 5 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 80 | 0.120 |
Why?
|
| Reverse Transcription | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cyclin E | 1 | 2014 | 13 | 0.120 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 19 | 0.120 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 18 | 0.120 |
Why?
|
| Urea | 1 | 2014 | 41 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 55 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 40 | 0.120 |
Why?
|
| Transfection | 1 | 2015 | 523 | 0.120 |
Why?
|
| Protein Binding | 4 | 2021 | 972 | 0.120 |
Why?
|
| Cell Survival | 2 | 2014 | 864 | 0.120 |
Why?
|
| Glycosylation | 2 | 2024 | 100 | 0.120 |
Why?
|
| Cell Line | 2 | 2014 | 1354 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2018 | 681 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 158 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1207 | 0.110 |
Why?
|
| Macrophage Activation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 70 | 0.110 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
| Genes, Viral | 1 | 2012 | 63 | 0.110 |
Why?
|
| Chemokines | 1 | 2013 | 97 | 0.110 |
Why?
|
| Serpins | 1 | 2012 | 27 | 0.110 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 33 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1039 | 0.110 |
Why?
|
| Eye Proteins | 1 | 2012 | 46 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 220 | 0.100 |
Why?
|
| Female | 4 | 2024 | 20969 | 0.090 |
Why?
|
| Protein Conformation | 2 | 2018 | 389 | 0.060 |
Why?
|
| Positive Transcriptional Elongation Factor B | 2 | 2015 | 14 | 0.060 |
Why?
|
| Proteomics | 2 | 2017 | 325 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2024 | 50 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2023 | 30 | 0.060 |
Why?
|
| Cysteine | 1 | 2024 | 98 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 68 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2023 | 55 | 0.060 |
Why?
|
| Models, Biological | 2 | 2018 | 677 | 0.060 |
Why?
|
| Metformin | 1 | 2024 | 65 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 173 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 109 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2024 | 353 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2018 | 808 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 190 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 661 | 0.050 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 45 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 197 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2020 | 7 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2024 | 1130 | 0.050 |
Why?
|
| Mannose | 1 | 2020 | 25 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 1095 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2020 | 58 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2020 | 57 | 0.050 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 23 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 129 | 0.040 |
Why?
|
| Oxygen | 1 | 2020 | 207 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 14 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2018 | 109 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 674 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2024 | 938 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2018 | 61 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 617 | 0.040 |
Why?
|
| Proteins | 1 | 2020 | 369 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 173 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 893 | 0.040 |
Why?
|
| Middle Aged | 2 | 2024 | 10129 | 0.040 |
Why?
|
| Lung | 1 | 2020 | 446 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 11712 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 162 | 0.030 |
Why?
|
| Virus Latency | 1 | 2015 | 42 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 14 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1371 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 167 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Vero Cells | 1 | 2014 | 93 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2023 | 1908 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 46 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 339 | 0.030 |
Why?
|
| Aged | 1 | 2024 | 6741 | 0.030 |
Why?
|
| Male | 2 | 2024 | 20025 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 73 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2012 | 151 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2014 | 933 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 190 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 444 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 243 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 260 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 935 | 0.020 |
Why?
|